Table 1.
The ELN Guidelines for assessing response to TKI therapy.
| Cytogenetic response | Ph+ve Metaphases analysed | Molecular response | % | Molecular remission | Total control genes ABL1; GUSB |
|---|---|---|---|---|---|
| No: >95% | 20/20 | Not reached | 100 | MR0 | ≥10,000; ≥24,000 |
| Partial: >35% | 6/20 | Not reached | >10 | MR1 | ≥10,000; ≥24,000 |
| Complete: 0% | 0/20 | Not reached | 1% | MR2 | ≥10,000; ≥24,000 |
| ND | MMR at ≥6mo | 0.1 | MR3 | ≥10,000; ≥24,000 | |
| 0/20 | MMR at ≥12mo | 0.01 | MR4 | ≥32,000; ≥77,000 | |
| ND | CMR | 0.001 | MR4.5 | ≥32,000; ≥77,000 | |
| ND | CMR | 0.0001 | MR5 | ≥100,000; ≥240,000 |